25
Participants
Start Date
June 11, 2021
Primary Completion Date
October 27, 2023
Study Completion Date
October 27, 2023
Olaparib+Bevacizumab to SCLC patients
"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
Samsung Medical Center, Seoul
Collaborators (1)
AstraZeneca
INDUSTRY
Roche Pharma AG
INDUSTRY
Se-Hoon Lee
OTHER